A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
← catalyst calendarNCT06090539 · readout in 434 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
460estimated
Sites
73
Countries
Chile, China, France +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-29 | actual | When the study began enrolling |
| Primary completion | 2027-10-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory Non-Hodgkin Lymphoma
Interventions
- Drug: BMS-986458
- Drug: Rituximab — also filed as Truxima
- Drug: Glofitamab/Obinutuzumab
- Drug: Mosunetuzumab
- Drug: Epcoritamab — also filed as GEN3013, Epkinly, Tepkinly
- Drug: Golcadomide — also filed as BMS-986369, CC-99282
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 2 years and 1 month
Number of participants with serious adverse events (SAEs)
measured Up to 2 years and 1 month
Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria
measured Up to Day 28
Number of participants with AEs leading to death
measured Up to 2 years and 1 month
Number of participants with AEs leading to discontinuation
measured Up to 2 years and 1 month
Number of participants with a complete response rate (CRR) according to the Lugano response criteria for Non-Hodgkin Lymphoma by Investigator assessment
measured Up to 2 years and 11 month
Publications
- PMID 41670385 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed